Management Team

Eva is a seasoned executive with over 25 years of experience in global financial operations, management and strategic planning. Before joining SOM Biotech, Eva served in multiple roles at Zimmer Biomet, most recently as Finance Director, CFO for Southern Europe, spanning across 5 countries. Prior to this, she held the role of Finance and Controlling Manager, Europe South West at Armacell Group, where she oversaw the finance, controlling and accounting departments.

Eva started her career at Baxter Healthcare, serving as an analyst in the sales, finance, and marketing departments. Following this, she spent over 11 years in multiple financial-based roles at Bosch Automative Steering, spending most of her time there serving as a Financial Manager in the USA, before eventually transitioning to Controlling Manager in Germany. Eva holds a Bachelor’s and a Master’s degree in Business Administration from the University of Barcelona. Following this, she completed the Advanced Management Programme at ESADE Business School, Barcelona. & Wharton Business School of the University of Pennsylvania, PA, USA.

Saurabh has been advising early-stage biotech companies for over 12 years.  He has specific expertise in the assessment of early-stage pipelines and analysis of the potential risks and rewards; portfolio management, leveraging simulation and decision trees; risk assessment of assets as well as the company and strategic decision making related to value creation.   Saurabh previously founded Farmantra, a life sciences corporate finance advisory firm, and is an Independent Expert for the European Commission. He has an MBA from ESADE Business School.

Oscar has more than 15 years’ experience in computational chemistry. He also has a strong track record in bio-informatics, chemistry and drug project management. Oscar holds a degree in Chemistry from the University of Barcelona, a degree in Biochemistry from the University Autonoma de Barcelona, and a Master’s degree in Computational Chemistry and Project Management from the University of Barcelona. His research during his studies was focused on computer-aided drug design in Alzheimer’s and in Phosphodiesterase inhibitors. At SOM, Oscar is responsible for the Company’s artificial intelligence drug discovery computational system.

Kevin McAllister has worked in the pharmaceutical industry for over 30 years.  Kevin joined the preclinical Nervous System research department of Sandoz and held positions of increasing responsibility up to Executive Director in Neuroscience at Novartis Institutes for Biomedical Research. Following this, Kevin worked as Principal Medical Scientific Expert in the Neuroscience Clinical Development Franchise where he contributed to projects with both pre- and post-marketing approval.  Kevin is Managing Director of Neurenable GmbH, a company dedicated to enable Neuroscience drug discovery and development. Kevin holds a PhD from the University of Wales, UK, and an MBA from the International Institute for Management Development, Lausanne, Switzerland.

Dr. C. Scart has more than 25 years of in-depth experience in the development and life-cycle management of innovative medicinal products in multinational pharmaceutical companies such as Janssen Cilag, Glaxo Wellcome, Recordati, and CSLBehring as a Clinical Development physician and Medical Director. Thereafter,she joined small biotechs (Pharnext as CMO, and Bioprojet as Head of Clinical Development) leading multi-national clinical development programs from Phase I to Phase IV across a broad range of therapeutic areas (mainly in neurology and rare diseases) and providing support for regulatory filings and interactions with FDA, EMA, and national regulatory authorities.

Her professional education as a Medical Doctor certified in Pediatrics also includes postgraduate Master’s degrees in Public Health (Pierre et Marie Curie Paris VI Medicine University), and in the Methodology of therapeutic evaluation (Lariboisière Paris VII Medicine University).

Dr. Insa has worked for more than 30 years in multinational pharmaceutical companies such as Parke-Davis (now Pfizer), UCB Pharma, Uriach Group (now Palau Pharma), and ISDIN (from Esteve Group), before establishing SOM Biotech. His experience is in drug development, from drug identification to commercialization, including clinical research and licensing. He was involved in the development of products like Quinapril, Tacrine, Cetirizine, Levetiracetam, Rupatadine, Dersalazine, Cimicoxib, Albaconazole, Gemfibrozil, Gabapentin, Piracetam, Levocetirizine, Nanocapsuled Cyclosporin, Disitertide, and others. He received his medical training and his PhD in Clinical Neurology from the University of Alicante, Spain; an MBA from ESADE Business School in Barcelona, and an Executive Education Program from IESE, Barcelona. He has also attended biotech leadership programs at Harvard Business School, Boston. His background includes more than 45 publications and papers, 7 chapters in books, 87 congress communications, and 9 pharmaceutical patents.